blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1615663

EP1615663 - AGENT FOR TREATING LEISHMANIA INFECTIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.11.2008
Database last updated on 14.09.2024
Most recent event   Tooltip23.07.2010Lapse of the patent in a contracting state
New state(s): HU		published on 25.08.2010  [2010/34]
Applicant(s)For all designated states
Mologen AG
Fabeckstrasse 30
14195 Berlin / DE
[2006/03]
Inventor(s)01 / WITTIG, Burghardt
Salzachstrasse 33
14129 Berlin / DE
02 / FUERTES-LOPEZ, Laura
C/Alonso Cano 72, 3o dcha
E-28003 Madrid / ES
03 / TIMON-JIMENEZ, Marcos
C/ Santa Clara 34, 2K
E-28200 San Lorenzo de El Escorial / ES
 [2006/03]
Representative(s)Boeckh, Tobias, et al
Hertin und Partner
Rechts- und Patentanwälte PartG mbB
Kurfürstendamm 54/55
10707 Berlin / DE
[N/P]
Former [2006/03]Boeckh, Tobias, et al
Hertin Anwaltssozietät Postfach 15 14 60
D-10676 Berlin / DE
Application number, filing date04790046.922.10.2004
[2006/03]
WO2004DE02383
Priority number, dateEP2003009036824.10.2003         Original published format: EP 03090368
[2006/03]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2005039633
Date:06.05.2005
Language:DE
[2005/18]
Type: A1 Application with search report 
No.:EP1615663
Date:18.01.2006
Language:DE
The application published by WIPO in one of the EPO official languages on 06.05.2005 takes the place of the publication of the European patent application.
[2006/03]
Type: B1 Patent specification 
No.:EP1615663
Date:26.12.2007
Language:DE
[2007/52]
Search report(s)International search report - published on:EP06.05.2005
ClassificationIPC:A61K39/008
[2006/03]
CPC:
C07K14/44 (EP,US); A61K31/7088 (EP,US); A61K39/008 (EP,US);
A61P33/02 (EP); C12N15/85 (EP,US); A61K2039/53 (EP,US);
Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/03]
Extension statesALNot yet paid
HRNot yet paid
LT14.11.2005
LV14.11.2005
MKNot yet paid
TitleGerman:MITTEL ZUR BEHANDLUNG VON INFEKTIONEN MIT LEISHMANIEN[2006/03]
English:AGENT FOR TREATING LEISHMANIA INFECTIONS[2006/03]
French:PRODUIT DE TRAITEMENT DES INFECTIONS PAR LEISHMANIA[2006/03]
Entry into regional phase14.11.2005National basic fee paid 
14.11.2005Designation fee(s) paid 
14.11.2005Examination fee paid 
Examination procedure10.05.2005Request for preliminary examination filed
International Preliminary Examining Authority: EP
14.11.2005Examination requested  [2006/03]
16.02.2006Despatch of a communication from the examining division (Time limit: M04)
10.05.2006Reply to a communication from the examining division
31.05.2006Despatch of a communication from the examining division (Time limit: M04)
29.09.2006Reply to a communication from the examining division
23.11.2006Despatch of a communication from the examining division (Time limit: M04)
28.11.2006Reply to a communication from the examining division
18.09.2007Communication of intention to grant the patent
06.11.2007Fee for grant paid
06.11.2007Fee for publishing/printing paid
Opposition(s)29.09.2008No opposition filed within time limit [2008/49]
Fees paidRenewal fee
21.09.2006Renewal fee patent year 03
26.07.2007Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ26.12.2007
EE26.12.2007
FI26.12.2007
PL26.12.2007
RO26.12.2007
SI26.12.2007
SK26.12.2007
BG26.03.2008
HU27.06.2008
[2010/34]
Former [2009/24]CZ26.12.2007
EE26.12.2007
FI26.12.2007
PL26.12.2007
RO26.12.2007
SI26.12.2007
SK26.12.2007
BG26.03.2008
Former [2009/22]CZ26.12.2007
EE26.12.2007
FI26.12.2007
PL26.12.2007
RO26.12.2007
SI26.12.2007
SK26.12.2007
Former [2008/39]CZ26.12.2007
FI26.12.2007
PL26.12.2007
RO26.12.2007
SI26.12.2007
SK26.12.2007
Former [2008/36]CZ26.12.2007
FI26.12.2007
PL26.12.2007
SI26.12.2007
Former [2008/26]FI26.12.2007
PL26.12.2007
SI26.12.2007
Former [2008/25]FI26.12.2007
PL26.12.2007
Cited inInternational search[XY]WO02098359  (CORIXA CORP [US], et al) [X] 1,3,6,8,13,14,17-20,22 * examples 19-23; claim - * [Y] 1-28;
 [XY]WO03031469  (MOLOGEN FORSCHUNGS ENTWICKLUNG [DE], et al) [X] 1,6-17,19,21-26 * example -; claim - * [Y] 1-28;
 [XY]  - LOPEZ-FUERTES L ET AL, "DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, (20021213), vol. 21, no. 3-4, ISSN 0264-410X, pages 247 - 257, XP004394510 [X] 1,6-10,12-17,19,21-24,26 * Zusammenfassung; Ergebnisse; Diskussion; * [Y] 1-28

DOI:   http://dx.doi.org/10.1016/S0264-410X(02)00450-4
 [XY]  - SKEIKY Y A W ET AL, "Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, (20020910), vol. 20, no. 27-28, ISSN 0264-410X, pages 3292 - 3303, XP004378524 [X] 1,3,6,8,13,14,17-20,22 * Zusammenfassung; Diskussion; * [Y] 1-28

DOI:   http://dx.doi.org/10.1016/S0264-410X(02)00302-X
 [XY]  - MENDEZ S ET AL, "Optimization of DNA vaccination against cutaneous leishmaniasis", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, (20021101), vol. 20, no. 31-32, ISSN 0264-410X, pages 3702 - 3708, XP004388612 [X] 1,2,6,8,13,14,17,19,22 * Zusammenfassung; Diskussion; * [Y] 1-28

DOI:   http://dx.doi.org/10.1016/S0264-410X(02)00376-6
 [XY]  - RAMREZ J R ET AL, "Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, (20011112), vol. 20, no. 3-4, ISSN 0264-410X, pages 455 - 461, XP004310152 [X] 1,8,13,14,17,19,22 * abstract * [Y] 1-28

DOI:   http://dx.doi.org/10.1016/S0264-410X(01)00341-3
 [XY]  - COTE-SIERRA JAVIER ET AL, "Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major", INFECTION AND IMMUNITY, (200201), vol. 70, no. 1, ISSN 0019-9567, pages 240 - 248, XP002317814 [X] 1,8,13,14,17,19,22 * abstract * [Y] 1-28

DOI:   http://dx.doi.org/10.1128/IAI.70.1.240-248.2002
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.